Literature DB >> 29525061

Comorbidities, Sociodemographic Factors, and Hospitalizations in Outpatients With Heart Failure and Preserved Ejection Fraction.

Vasiliki V Georgiopoulou1, Arash Velayati2, Greg Burkman1, Song Li1, Kanwal Farooq1, Ayman Samman-Tahhan1, Lampros Papadimitriou3, Javed Butler3, Andreas P Kalogeropoulos4.   

Abstract

Patients with heart failure and preserved ejection fraction (HFpEF) tend to be older and have a high co-morbidity burden. The impact of co-morbid conditions and sociodemographic risk factors on outcomes in these patients has not been quantified. We evaluated 445 consecutive outpatients with HFpEF, defined as established diagnosis of heart failure (HF) with left ventricular ejection fraction at presentation >40% and no previous left ventricular ejection fraction ≤40%. Patients with specific cardiomyopathies, congenital heart disease, primary right-sided disease, valvular disease, or previous advanced HF therapies were excluded. After 2 years, there were 44 deaths and 609 all-cause hospitalizations; of these, 260 (42.7%) were cardiovascular hospitalizations, including HF, and 173 (28.4%) were specifically for HF. The highest attributable risk for hospitalizations was associated with marital status (single, divorced, and widowed had higher hospitalization rates compared with married patients), hypoalbuminemia, diabetes, atrial fibrillation, and renal dysfunction. The proportion of hospitalizations potentially attributable to these factors was 66.6% (95% confidence interval [CI] 56.4 to 74.4) for all-cause hospitalizations, 76.9% (95% CI 65.2 to 84.6) for cardiovascular hospitalizations, and 83.0% (95% CI 70.3 to 90.3) for HF hospitalizations. For composite end points, the proportion was 46.9% (95% CI 34.0% to 57.3%) for death or all-cause hospitalization, 45.7% (95% CI 29.3% to 58.2%) for death or cardiovascular hospitalization, and 43.7% (95% CI 24.2% to 58.2%) for death or HF-related hospitalization. In conclusion, among outpatients with HFpEF, most hospitalizations could be attributed to co-morbidities and sociodemographic factors. Effects of HF therapies on hospitalizations and related end points may be difficult to demonstrate in these patients. Multidisciplinary approaches are more likely to impact hospitalizations in HFpEF.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29525061     DOI: 10.1016/j.amjcard.2018.01.040

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives.

Authors:  Miguel Camafort-Babkowski; Akintunde Adeseye; Antonio Coca; Albertino Damasceno; Giovanni De Simone; Maria Dorobantu; Pardeep S Jhund; Kazuomi Kario; Takahiro Komori; Hae Young Lee; Patricio López-Jaramillo; Okechukwu Ogah; Sandosh Padmanabahn; Domingo A Pascual-Figal; Wook Bum Pyun; Nicolás Federico Renna; Weimar Kunz Sebba Barroso; Osiris Valdez-Tiburcio; Fernando Stuardo Wyss-Quintana
Journal:  J Hum Hypertens       Date:  2020-11-25       Impact factor: 3.012

2.  Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.

Authors:  Linda Alex; Ilaria Russo; Volodymir Holoborodko; Nikolaos G Frangogiannis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-13       Impact factor: 4.733

3.  Prognostic role of albumin level in heart failure: A systematic review and meta-analysis.

Authors:  Mahmoud El Iskandarani; Bara El Kurdi; Ghulam Murtaza; Timir K Paul; Marwan M Refaat
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

4.  Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT.

Authors:  Bin Dong; Xin He; Ruicong Xue; Yili Chen; Jingjing Zhao; Wengen Zhu; Weihao Liang; Zexuan Wu; Dexi Wu; Huiling Huang; Yuanyuan Zhou; Yugang Dong; Chen Liu
Journal:  ESC Heart Fail       Date:  2020-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.